|
Oct. 18, 2010 |
|
|
Dec. 17, 2018 |
|
|
jRCT2080221270 |
A Safety and Efficacy Extension Study of ONO-4641 in Patients with Relapsing-Remitting Multiple Sclerosis |
|
A Safety and Efficacy Extension Study of ONO-4641 in Patients with Relapsing-Remitting Multiple Sclerosis |
ONO PHARMACEUTICAL CO.,LTD. |
||
y.tani@ono.co.jp |
||
| 343 | ||
Interventional |
||
dose-blind, randomized |
||
2 |
||
Completed 26 weeks of double-blind phase of Study ONO-4641POU006 |
||
Presence of any dermatological abnormalities during Study ONO-4641POU006 that could increase the risk of the patient developing a skin cancer. |
||
| 18age old over | ||
| 55age old under | ||
Both |
||
Relapsing-Remitting Multiple Sclerosis |
||
investigational material(s) |
||
the long-term safety and tolerability of ONO-4641 |
||
the number of Gd-enhanced lesions, lesion volume, and brain volume obtained by MRI |
||
| ONO PHARMACEUTICAL CO.,LTD. | |
| JapicCTI-101307 | |